Patent application number | Description | Published |
20130297578 | INTEGRATED CIRCUIT DEVICE AND METHOD FOR DETERMINING AN INDEX OF AN EXTREME VALUE WITHIN AN ARRAY OF VALUES - An integrated circuit device comprises at least one digital signal processor, DSP, module, the at least one DSP module comprising a plurality of data registers and at least one data execution unit, DEU, module arranged to execute operations on data stored within the data registers. The at least one DEU module is arranged to, in response to receiving an extreme value index instruction, compare a previous extreme value located within a first data register set of the DSP module with at least one input vector data value located within a second data register set of the DSP module, and determine an extreme value thereof. The at least one DEU module is further arranged to, if the determined extreme value comprises an input vector data value located within the second data register set, store the determined extreme value in the first data register set, determine an index value for the determined extreme value, and store the determined index value in the first data register set. | 11-07-2013 |
20150356054 | DATA PROCESSOR AND METHOD FOR DATA PROCESSING - A integrated circuit device has at least one instruction processing module arranged for executing vector data processing upon receipt of a respective one of a set of data processing instructions. The data processing instructions include at least one matrix processing instruction for processing elements of a matrix. The elements of rows of the matrix are stored in a set of register, and the instruction processing module comprising an accessing unit for accessing selected elements of the matrix, which selected elements are non-sequentially located according to a predetermined pattern across multiple registers of the set of registers, the accessing enabling respective processing lanes to write or read different registers. Advantageously elements in columns of a matrix can efficiently be processed. | 12-10-2015 |
Patent application number | Description | Published |
20080319066 | Jasmonate Derivative Compounds, Pharmaceuticals Compounds and Methods of Use Thereof - The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers. | 12-25-2008 |
20090291904 | CHEMICAL DERIVATIVES OF JASMONATE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers. | 11-26-2009 |
20100003346 | COMBINATION METHODS OF TREATING CANCER - The present invention relates to compositions and methods for treating cancer, by administering a combination comprising a jasmonate derivative (e.g., methyl jasmonate or a compound of any of formulae I through VII or any of the jasmonate derivatives exemplified by such formulae) and at least one other agent selected from a chemotherapeutic agent (e.g., a nitroso-urea, a platinum compound, a taxane derivative, an antitumor antibiotic) and an inhibitor of glycolysis (e.g., 2-deoxy-D-glucose). The jasmonate derivative and the at least one other agent together provide a therapeutic effect, which is preferably synergistic (cooperative). | 01-07-2010 |
20100087384 | JASMONATE BASED ASSAYS FOR IDENTIFYING COMPOUNDS THAT SELECTIVELY INHIBIT MITOCHONDRIAL BOUND HEXOKINASES - The present invention provides compositions comprising compounds that selectively bind to hexokinases thereby promoting dissociation of these enzymes from mitochondria, and methods of use of such compounds and compositions to induce cell death in diseases and disorders characterized by the high levels of mitochondrial bound hexokinase. The present invention further discloses methods and assays for detecting and identifying molecules having these activities. | 04-08-2010 |
20130045933 | ALOE-EMODIN DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER - The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageously, these derivatives are potent cytotoxic agents against a variety of anthracycline-resistant tumors. In addition, they may have reduced cardiotoxicity. As such, the novel compounds of the invention offer an advantage over currently available drugs. The present invention further relates to methods for preparing the novel Aloe-Emodin Glycoside (AEG) based derivatives, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers. | 02-21-2013 |
20130203689 | CHEMICAL DERIVATIVES OF JASMONATE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers. | 08-08-2013 |
Patent application number | Description | Published |
20080237482 | Variable collimation in radiation detection - Apparatus for detecting radiation emitted from a number of volume elements of a body. The apparatus includes a first plurality of detector elements, each detector element being configured to output signals indicative of an intensity of radiation that is incident thereon. The apparatus also includes a first plurality of adjustable collimator channels, each adjustable collimator channel being associated with and being positioned between a respective detector element and the body, each adjustable collimator channel having a second plurality of dimensional configurations defining respective different sets of the volume elements from which emitted radiation impinges on the respective detector element. A processor computes a radiation intensity from at least a portion of the volume elements in response to the signals output by the detector elements in at least two of the dimensional configurations of the adjustable collimator channels. | 10-02-2008 |
20100086098 | Method, Apparatus, and System of Reducing Polarization in Radiation Detectors - Method, apparatus and system for reducing or preventing polarization in semiconductor radiation detectors for medical imaging. For example, an apparatus includes a semiconductor with electrodes coupled thereto, configured to generate an electrical signal in the electrodes in response to absorption of ionizing radiation in the semiconductor, wherein the absorption of the ionizing radiation generates a space charge in the semiconductor; and an infra-red (IR) generator configured to generate IR radiation of a selectable wavelength, the selectable wavelength being chosen so as to at least partially reduce an effect of the space charge on the electrical signal. | 04-08-2010 |
20130126998 | RADIATION DETECTORS AND METHODS OF FABRICATING RADIATION DETECTORS - Radiation detectors and methods of fabricating radiation detectors are provided. One method includes mechanically polishing at least a first surface of a semiconductor wafer using a polishing sequence including a plurality of polishing steps, wherein a last polishing step of the polishing sequence includes polishing with a slurry having a grain size smaller than about 0.1 μm to create a polished first surface. The method also includes applying (i) an encapsulation layer on a top of the polished first surface to seal the polished first surface and (ii) a photoresist layer on top of the encapsulation layer on the polished first surface. The method further includes creating undercuts of the encapsulation layer under the photoresist layer. The method additionally includes partially etching the polished first surface of the semiconductor via the openings in the photoresist layer and in the encapsulation layer to partially etch the semiconductor creating etched regions. | 05-23-2013 |
20130133568 | SYSTEMS AND METHODS FOR CRYSTAL GROWTH - Systems and methods for crystal growth are provided. One method includes producing a lateral thermal profile in a furnace having a crucible therein containing a material for growing a crystal. The lateral thermal profile has three zones, wherein the first and third zones have temperatures above and below a melting point of the material, respectively, and the second zone has a plurality of temperatures with at least one temperature equal to the melting point of the material. The method further includes combining the lateral thermal profile with a vertical thermal gradient produced in the furnace, wherein the vertical thermal gradient causes a point in a bottom of the crucible located in the third zone to be the coldest point in the crucible. The method also includes transferring heat from the first and second zones to the third zone to produce a leading edge of the interface. | 05-30-2013 |
20140048714 | APPARATUS AND METHODS FOR CHARGE COLLECTION CONTROL IN RADIATION DETECTORS - Apparatus and methods for charge collection control in radiation detectors are provided. One radiation detector includes a semiconductor substrate, at least one cathode on a surface of the semiconductor substrate, and a plurality of anodes on a surface of the semiconductor substrate opposite the at least one cathode, wherein the plurality of anodes have gaps therebetween. The radiation detector further includes a charge collection control arrangement configured to cause one or more charges induced within the semiconductor substrate by incident photons to drift towards one or more of the plurality of anodes. | 02-20-2014 |
20140084171 | SYSTEMS AND METHODS FOR SCANNING WITH RADIATION DETECTORS - Systems and methods for scanning with radiation detectors are provided. One system includes at least one radiation scanning camera-head, an array of at least one pixelated radiation detector having an imaging surface including a two dimensional array of pixels, and a scanning unit positioned between the radiation detector and the object. The scanning unit includes first and second radiation blocking plates having first and second two-dimensional arrays of openings, respectively, wherein the array of pixels and the first and second arrays of openings have a same pitch. Additionally, for each of a plurality of scan positions of the scanning unit, the first and second moveable plates and the imaging surface are positioned differently with respect to each other to produce different inclination angles in response to each scan position. | 03-27-2014 |
20140138556 | COLLIMATORS FOR SCAN OF RADIATION SOURCES AND METHODS OF SCANNING - Collimators for two-dimensional scans of a radiation sources and methods of scanning are provided. One system includes a scan unit for scanning and collecting ionizing radiation emitted from a radiation emitting object is provided. The scan unit includes an array of at least one pixelated radiation detector having an imaging surface including a two-dimensional (2D) array of pixels. The scan unit also includes a collimator positioned between the radiation detector and the radiation emitting object, with the collimator including a 2D array of columns having openings and septa forming bores, wherein the columns are arranged in groups along rows of the 2D array of columns and the bores within one of the groups have a different aspect ratios than the bores in another one of the groups. | 05-22-2014 |
20150063671 | SYSTEMS AND METHODS FOR SUMMING SIGNALS FROM AN IMAGING DETECTOR - A system includes a detector and a processing module. The detector includes pixels configured to detect an event corresponding to energy from a radiopharmaceutical. The processing module is configured to receive a request for each pixel that detects energy during a reading cycle. The processing module is configured to determine an energy level for each requesting pixel. For each requesting pixel, the processing module is configured to count the event when the energy level corresponds to an energy of the radiopharmaceutical, and to determine a combined energy level of the pixel and at least one adjacent pixel when the energy level does not correspond. The processing module is configured to count the event when the combined energy level corresponds to the energy of the radiopharmaceutical, and to disregard the event when the combined energy level does not correspond to the energy of the radiopharmaceutical. | 03-05-2015 |
Patent application number | Description | Published |
20130179705 | Controlling A Turbo Mode Frequency Of A Processor - In one embodiment, the present invention includes a multicore processor with a power controller to control a frequency at which the processor operates. More specifically, the power controller can limit a maximum operating frequency of the processor to less than a configured maximum operating frequency to enable a reduction in a number of frequency transitions occurring responsive to power state events, thus avoiding the overhead of operations performed in handling such transitions. Other embodiments are described and claimed. | 07-11-2013 |
20130179709 | Controlling Operating Frequency Of A Core Domain Via A Non-Core Domain Of A Multi-Domain Processor - In one embodiment, the present invention includes a method for determining that a non-core domain of a multi-domain processor is not operating at a frequency requested by the non-core domain, sending a request from the non-core domain to a power controller to reduce a frequency of a core domain of the multi-domain processor, and responsive to the request, reducing the core domain frequency. Other embodiments are described and claimed. | 07-11-2013 |
20150095673 | Controlling A Turbo Mode Frequency Of A Processor - In one embodiment, the present invention includes a multicore processor with a power controller to control a frequency at which the processor operates. More specifically, the power controller can limit a maximum operating frequency of the processor to less than a configured maximum operating frequency to enable a reduction in a number of frequency transitions occurring responsive to power state events, thus avoiding the overhead of operations performed in handling such transitions. Other embodiments are described and claimed. | 04-02-2015 |
Patent application number | Description | Published |
20080207516 | CO-ADMINISTRATION OF A POLYSACCHARIDE WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CANCER - Disclosed herein are compositions and methods for treating diseases such as cancer. The compositions comprise one or more polysaccharides in an admixture with one or more therapeutic agents. This admixture can be administered to a subject in need thereof using any known method of administration. The therapeutic agent, if administered alone, can cause undesirable side-effects in the subject. The polysaccharide component minimizes or eliminates these side effects. The compositions described herein effectuate an enhanced therapeutic effect along with reduced toxicity. | 08-28-2008 |
20080286251 | Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins - Described herein is a microbial composition used to enhance anti-cancer drugs. Specifically, microbial compositions that comprise a part of or an entire microorganism having surface lectins specific to carbohydrate moieties on tumor surface combined with an oncolytic agent. | 11-20-2008 |
20120157407 | GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis. | 06-21-2012 |
20120282220 | GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis. | 11-08-2012 |
20130131010 | GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis. | 05-23-2013 |
20130171151 | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease - Aspects of the invention provide methods for treatment of nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate compound for the treatment of nonalcoholic steatohepatitis and associated liver fibrosis. | 07-04-2013 |
20130259870 | Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease - Aspects of the invention provides provide methods for treatment of NASH and associated liver fibrosis. In particular, aspects of the invention relate to the therapeutic formulation comprising a galactomannan polysaccharide compound for the treatment of NASH and associated liver fibrosis. | 10-03-2013 |
20130261078 | Compositions of novel carbohydrate drug for treatment of human diseases - Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues. | 10-03-2013 |
20140086932 | METHOD FOR ENHANCING SPECIFIC IMMUNOTHERAPIES IN CANCER TREATMENT - Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer. | 03-27-2014 |
20140350238 | COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES - Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues. | 11-27-2014 |
20150147338 | GALACTO-RHAMNOGALACTURONATE COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED INDUCIBLE NITRIC OXIDE SYNTHASE - Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. | 05-28-2015 |
20150174151 | COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES - Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues. | 06-25-2015 |